297 related articles for article (PubMed ID: 25983041)
1. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.
Eigl BJ; North S; Winquist E; Finch D; Wood L; Sridhar SS; Powers J; Good J; Sharma M; Squire JA; Bazov J; Jamaspishvili T; Cox ME; Bradbury PA; Eisenhauer EA; Chi KN
Invest New Drugs; 2015 Aug; 33(4):969-76. PubMed ID: 25983041
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.
Chu QS; Nielsen TO; Alcindor T; Gupta A; Endo M; Goytain A; Xu H; Verma S; Tozer R; Knowling M; Bramwell VB; Powers J; Seymour LK; Eisenhauer EA
Ann Oncol; 2015 May; 26(5):973-981. PubMed ID: 25632070
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Razak AR; Hotte SJ; Siu LL; Chen EX; Hirte HW; Powers J; Walsh W; Stayner LA; Laughlin A; Novotny-Diermayr V; Zhu J; Eisenhauer EA
Br J Cancer; 2011 Mar; 104(5):756-62. PubMed ID: 21285985
[TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN
Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.
Hotte SJ; Chi KN; Joshua AM; Tu D; Macfarlane RJ; Gregg RW; Ruether JD; Basappa NS; Finch D; Salim M; Winquist EW; Torri V; North S; Kollmannsberger C; Ellard SL; Eigl BJ; Tinker A; Allan AL; Beja K; Annala M; Powers J; Wyatt AW; Seymour L;
Clin Genitourin Cancer; 2019 Jun; 17(3):201-208.e1. PubMed ID: 31056399
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Templeton AJ; Dutoit V; Cathomas R; Rothermundt C; Bärtschi D; Dröge C; Gautschi O; Borner M; Fechter E; Stenner F; Winterhalder R; Müller B; Schiess R; Wild PJ; Rüschoff JH; Thalmann G; Dietrich PY; Aebersold R; Klingbiel D; Gillessen S;
Eur Urol; 2013 Jul; 64(1):150-8. PubMed ID: 23582881
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
10. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Climent MÁ; Pérez-Valderrama B; Mellado B; Fernández Parra EM; Fernández Calvo O; Ochoa de Olza M; Muinelo Romay L; Anido U; Domenech M; Hernando Polo S; Arranz Arija JÁ; Caballero C; Juan Fita MJ; Castellano D
Eur J Cancer; 2017 Dec; 87():30-37. PubMed ID: 29102858
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Antonarakis ES; Tagawa ST; Galletti G; Worroll D; Ballman K; Vanhuyse M; Sonpavde G; North S; Albany C; Tsao CK; Stewart J; Zaher A; Szatrowski T; Zhou W; Gjyrezi A; Tasaki S; Portella L; Bai Y; Lannin TB; Suri S; Gruber CN; Pratt ED; Kirby BJ; Eisenberger MA; Nanus DM; Saad F; Giannakakou P;
J Clin Oncol; 2017 Oct; 35(28):3181-3188. PubMed ID: 28632486
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.
Zorzi AP; Bernstein M; Samson Y; Wall DA; Desai S; Nicksy D; Wainman N; Eisenhauer E; Baruchel S
Pediatr Blood Cancer; 2013 Nov; 60(11):1868-74. PubMed ID: 23893953
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.
Yu SS; Athreya K; Liu SV; Schally AV; Tsao-Wei D; Groshen S; Quinn DI; Dorff TB; Xiong S; Engel J; Pinski J
Clin Genitourin Cancer; 2017 Dec; 15(6):742-749. PubMed ID: 28668277
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Yong WP; Goh BC; Soo RA; Toh HC; Ethirajulu K; Wood J; Novotny-Diermayr V; Lee SC; Yeo WL; Chan D; Lim D; Seah E; Lim R; Zhu J
Ann Oncol; 2011 Nov; 22(11):2516-2522. PubMed ID: 21385886
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
[TBL] [Abstract][Full Text] [Related]
16. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Hussain M; Carducci MA; Slovin S; Cetnar J; Qian J; McKeegan EM; Refici-Buhr M; Chyla B; Shepherd SP; Giranda VL; Alumkal JJ
Invest New Drugs; 2014 Oct; 32(5):904-12. PubMed ID: 24764124
[TBL] [Abstract][Full Text] [Related]
18. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
19. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
